col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world


24 Results       Page 1

 [1] 
Springer-Verlag: DARU Journal of Pharmaceutical Sciences
  original article Date Title Authors   All Authors
1 [GO] 2025―Jan―03 Evaluation of the consumption pattern and efficacy of Linezolid in COVID-19 hospitalized patients in a hospital in Tehran-Iran Alireza Tavasoli Rostami, Morteza Izadi, Mohsen Saberi, Mehdi Raei, Mostafa Soodmand, Khadijeh Nasiri, et al. (+2)
2 [GO] 2024―Jul―19 Plausible mechanism of drug resistance and side-effects of COVID-19 therapeutics: a bottleneck for its eradication Swarnali Das, Sreyashi Nath, Sanjay Kumar Dey
3 [GO] 2024―Apr―23 Deciphering the similarities and disparities of molecular mechanisms behind respiratory epithelium response to HCoV-229E and SARS-CoV-2 and drug repurposing, a systems biology approach Zeinab Dehghan, Seyed Amir Mirmotalebisohi, Maryam Mozafar, Marzieh Sameni, Fatemeh Saberi, Amin Derakhshanfar, et al. (+3)
4 [GO] 2023―Oct―31 Computational Screening Using a Combination of Ligand-Based Machine Learning and Molecular Docking Methods for the Repurposing of Antivirals Targeting the SARS-CoV-2 Main Protease Gusti Putu Wahyunanda Crista Yuda, Naufa Hanif, Adam Hermawan
5 [GO] 2023―Aug―19 COVID-19: A novel holistic systems biology approach to predict its molecular mechanisms (in vitro) and repurpose drugs Marzieh Sameni, Seyed Amir Mirmotalebisohi, Sadaf Dadashkhan, Sepideh Ghani, Maryam Abbasi, Effat Noori, Hakimeh Zali
6 [GO] 2023―Aug―19 Correction: Flavonoid as possible therapeutic targets against COVID-19: a scoping review of in silico studies Larissa Toigo, Emilly Isabelli dos Santos Teodoro, Ana Carolina Guidi, Naiara Cássia Gancedo, Marcus Vinícius Petruco, Eduardo Borges Melo, et al. (+6)
7 [GO] 2023―May―17 Flavonoid as possible therapeutic targets against COVID-19: a scoping review of in silico studies Larissa Toigo, Emilly Isabelli dos Santos Teodoro, Ana Carolina Guidi, Naiara Cássia Gancedo, Marcus Vinícius Petruco, Eduardo Borges Melo, et al. (+6)
8 [GO] 2022―Sep―02 A comparison between SARS-CoV-1 and SARS-CoV2: an update on current COVID-19 vaccines Gelareh Abdolmaleki, Mina Azam Taheri, Sarina Paridehpour, Neshaut Mashreghi Mohammadi, Yasaman Ahmadi Tabatabaei, Taraneh Mousavi, Mohsen Amin
9 [GO] 2022―May―04 Design, synthesis and docking study of Vortioxetine derivatives as a SARS-CoV-2 main protease inhibitor Hemant Suryavanshi, Raju D. Chaudhari, Vishakha Patil, Swapan Majumdar, Sudhan Debnath, Goutam Biswas
10 [GO] 2022―Apr―27 West African medicinal plants and their constituent compounds as treatments for viral infections, including SARS-CoV-2/COVID-19 Temidayo D. Popoola, Peter A. Segun, Edmund Ekuadzi, Rita A. Dickson, Olanrewaju R. Awotona, Lutfun Nahar, et al. (+2)
11 [GO] 2022―Feb―02 Glucosinolates and their hydrolysis products as potential nutraceuticals to combat cytokine storm in SARS-COV-2 Saba Rahimi Bahoosh, Yalda Shokoohinia, Mahdieh Eftekhari
12 [GO] 2022―Jan―27 Comparing the efficacy of tocilizumab with corticosteroid therapy in treating COVID-19 patients: a systematic review and meta-analysis Phei Ching Lim, Kar Loon Wong, Retha Rajah, Meng Fei Chong, Ting Soo Chow, Sivasangari Subramaniam, Chong Yew Lee
13 [GO] 2022―Jan―24 Calcineurin inhibitors and related medicines: a cohort study examining England’s primary care prescription changes during the COVID-19 pandemic (January 2019 to March 2021) Ravina Barrett
14 [GO] 2021―Nov―11 Characteristics of published/registered clinical trials on COVID-19 treatment: A systematic review Pooria Asili, Maryam Mirahmad, Ozra Tabatabaei-Malazy, Azadeh Manayi, Elahe Haghighat, Mohammad Mahdavi, Bagher Larijani
15 [GO] 2021―Mar―13 Surging trends in prescriptions and costs of antidepressants in England amid COVID-19 Shahad A. Rabeea, Hamid A. Merchant, Muhammad Umair Khan, Chia Siang Kow, Syed Shahzad Hasan
16 [GO] 2020―Aug―28 Comparing outcomes of hospitalized patients with moderate and severe COVID-19 following treatment with hydroxychloroquine plus atazanavir/ritonavir Hamid Rahmani, Effat Davoudi-Monfared, Anahid Nourian, Morteza Nabiee, Setayesh Sadeghi, Hossein Khalili, et al. (+7)
17 [GO] 2020―Aug―27 COVID-19 vaccines: ethical framework concerning human challenge studies Daniela Calina, Thomas Hartung, Anca Oana Docea, Demetrios A. Spandidos, Alex M. Egorov, Michael I. Shtilman, et al. (+2)
18 [GO] 2020―Aug―18 Is there any potential management against COVID-19? A systematic review and meta-analysis Haleh Talaie, Sayed Masoud Hosseini, Maryam Nazari, Yadollah Fakhri, Atieh Mousavizadeh, Hossein Vatanpour, Ali Firoozfar
19 [GO] 2020―Aug―15 The application of direct viral cytopathic hypothesis to design drug trials in the battle against COVID-19 Mohammad Ali Ashraf, Alireza Sherafat, Alieh Pourdast, Pershang Nazemi, Minoo Mohraz
20 [GO] 2020―Jul―30 Classification of the present pharmaceutical agents based on the possible effective mechanism on the COVID-19 infection Maryam Amini Pouya, Seyyedeh Maryam Afshani, Armin Salek Maghsoudi, Shokoufeh Hassani, Kayvan Mirnia
21 [GO] 2020―Jul―03 Short and long term impacts of COVID-19 on the pharmaceutical sector Nayyereh Ayati, Parisa Saiyarsarai, Shekoufeh Nikfar
22 [GO] 2020―Jun―25 Diabetes management during Ramadan amid Covid-19 pandemic Ali Tootee, Ensieh Nasli Esfahani, Bagher Larijani
23 [GO] 2020―Jun―19 The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia: a single centered, retrospective, observational study Ensieh Vahedi, Mostafa Ghanei, Ali Ghazvini, Hossein Azadi, Morteza Izadi, Yunes Panahi, et al. (+12)
24 [GO] 2020―May―08 COVID-19 and off label use of drugs: an ethical viewpoint Amirahmad Shojaei, Pooneh Salari
 [1] 

24 Results       Page 1


[de][en]

Last change 2025―Jul―29 14:55:09 UTC

© Daten-Quadrat 2022       Done in 0.004 sec